S. Khalilieh

发表

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects

J. Brejda, J. Butterton, K. Yee, 2017, Clinical Drug Investigation.

Pharmacokinetics, safety and tolerability of long‐acting parenteral intramuscular injection formulations of doravirine

K. Yee, S. Mittal, S. Stoch, 2020, Journal of clinical pharmacy and therapeutics.

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans

J. Butterton, K. Yee, Yuexia Liang, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics

K. Lasseter, T. Marbury, K. Yee, 2017, Journal of clinical pharmacology.

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects

M. Lai, K. Yee, M. Iwamoto, 2016, Antimicrobial Agents and Chemotherapy.

Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects

Rachel Liu, K. Yee, R. Sanchez, 2018, Journal of clinical pharmacology.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

R. Preston, T. Marbury, K. Yee, 2018, Antimicrobial Agents and Chemotherapy.

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

D. Rader, D. Connolly, Jiajun Liu, 2012, Science Translational Medicine.

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects

H. Magnussen, H. Watz, O. Holz, 2009, European Respiratory Journal.

Effect of tildrakizumab (MK‐3222), a high affinity, selective anti‐IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis

M. Iwamoto, M. Martinho, P. Shaw, 2018, British journal of clinical pharmacology.

Medications in Patients with Dementia and Behavioral Disturbance

T. Voss, R. Khandker, E. Bortnichak, 2021, Journal of Alzheimer's disease reports.

The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.

L. Hanson, D. Dale, S. Huyck, 2015, Cytokine.

Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.

M. Seiberling, P. Stryszak, Xuewen Ma, 2013, International immunopharmacology.

Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

Christine R. Xu, P. Hodsman, D. Montgomery, 2018, Basic & clinical pharmacology & toxicology.

Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety

Samir K. Gupta, Zaiqi Wang, B. Prenner, 2006, Expert opinion on drug safety.

Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions

J. Butterton, L. Wenning, Hwa-ping Feng, 2015, Clinical Pharmacokinetics.

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions

L. V. Van Bortel, K. Yee, R. Sanchez, 2019, Antimicrobial Agents and Chemotherapy.

Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin

Yang Liu, K. Yee, Tamara D. Cabalu, 2020, Journal of clinical pharmacology.

Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone

K. Yee, R. Sanchez, M. Iwamoto, 2019, Clinical pharmacology in drug development.

Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir

K. Yee, R. Sanchez, S. Stoch, 2019, Antimicrobial Agents and Chemotherapy.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers

K. Yee, M. Iwamoto, Rachael Liu, 2017, Clinical Drug Investigation.

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study

K. Yee, R. Sanchez, M. Iwamoto, 2016, Antimicrobial Agents and Chemotherapy.

Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects.

A. Zandvliet, A. Mehta, Christine R. Xu, 2015, International journal of clinical pharmacology and therapeutics.

Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate

K. Yee, S. Stoch, M. Iwamoto, 2020, AAPS PharmSciTech.

Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate

K. Yee, S. Stoch, M. Iwamoto, 2020, AAPS PharmSciTech.

A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid‐Reducing Agents

K. Yee, R. Sanchez, M. Iwamoto, 2019, Journal of clinical pharmacology.

Clinical improvement in psoriasis with specific targeting of interleukin-23

H. Kittler, T. Mcclanahan, A. Zandvliet, 2015, Nature.

Effect of Meal Timing Not Critical for the Pharmacokinetics of Tegaserod (HTF 919)

Honghui Zhou, M. Guerret, H. Lau, 1999, Journal of clinical pharmacology.

Pharmacokinetics of desloratadine in children between 2 and 11 years of age.

Samir K. Gupta, C. Banfield, B. Kantesaria, 2007, British journal of clinical pharmacology.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

M. Rizk, J. Butterton, K. Yee, 2017, Clinical Pharmacokinetics.

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions

K. Yee, R. Sanchez, S. Stoch, 2020, Clinical Drug Investigation.